HC Wainwright Has Strong Estimate for ALDX FY2029 Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Research analysts at HC Wainwright boosted their FY2029 earnings estimates for Aldeyra Therapeutics in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will earn $1.10 per share for the year, up from their previous estimate of $1.00. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.08.

Separately, BTIG Research cut their price target on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, April 7th.

Aldeyra Therapeutics Stock Performance

ALDX stock opened at $2.42 on Tuesday. The company has a market capitalization of $144.95 million, a P/E ratio of -2.49 and a beta of 0.92. The company has a 50-day simple moving average of $3.47 and a 200 day simple moving average of $4.71. Aldeyra Therapeutics has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Institutional Trading of Aldeyra Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its position in shares of Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock worth $353,000 after purchasing an additional 48,313 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Aldeyra Therapeutics by 14.4% in the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 2,822 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new stake in shares of Aldeyra Therapeutics in the fourth quarter worth approximately $69,000. AlphaCentric Advisors LLC purchased a new stake in shares of Aldeyra Therapeutics in the fourth quarter worth approximately $234,000. Finally, Boston Financial Mangement LLC purchased a new stake in shares of Aldeyra Therapeutics in the fourth quarter worth approximately $141,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company’s stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. This represents a 36.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.60% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.